Category: News - Part 3

Callisto’s Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis

NEW YORK, Jan. 24 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(Frankfurt”>CA4), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced that Dr. Kunwar Shailubhai will be giving an invited presentation on Atiprimod, the Company’s anti-cancer drug candidate, at the GTCbio conference on February 8-9,…

Publication of Early Research on Callisto Pharmaceutical’s Degrasyn Drug Class Suggests Potential to Treat Brain Tumors

Paper Published in Oncogene Highlights Animal Model Data on Degrasyn Drug Candidate WP1066 NEW YORK, Jan. 23 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today a recent publication by a research group at the University of Texas M….

First Berlin Releases Research Update Following Callisto Pharmaceutical’s Announcement of $5.75 Million Preferred Stock Financing

Independent German Based Equity Research Firm Maintains Buy Rating, Speculative Risk Rating and Projected Share Price Target of $2.00 NEW YORK, Jan. 5 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that a leading independent research firm, First…

Callisto Pharmaceuticals CEO Releases Letter to Shareholders Describing Recent Accomplishments

NEW YORK, Jan. 4 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL); (FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today released a letter to shareholders from CEO Gary S. Jacob. In the letter, Dr. Jacob summarizes the Company’s recent accomplishments during the last few months…

CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ATIPRIMOD FOR MULTIPLE MYELOMA INDICATION

NEW YORK–(BUSINESS WIRE)–January 6, 2004 –Callisto Pharmaceuticals, Inc. (OTCBB: CLSP – News) announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to the company’s lead drug candidate, Atiprimod, for the treatment of multiple myeloma, a blood cancer that proliferates in bone…

RESEARCH PRESENTED ON CALLISTO PHARMACEUTICALS’ LEAD DRUG CANDIDATE FOR MULTIPLE MYELOMA

Callisto Pharmaceuticals, Inc. (OTCBB:CLSP) today announced that researchers at Dana-Farber Cancer Institute (Boston) and The University of Texas M. D. Anderson Cancer Center (Houston) presented preclinical data on Atiprimod, Callisto Pharmaceuticals’ lead drug candidate for multiple myeloma, at oral and poster presentations given at the 45th Annual Meeting of the American Society of Hematology, held…

Callisto Pharmaceuticals Announces Appointment of Chairman of Scientific Advisory Board

Callisto Pharmaceuticals, Inc. (OTC BB: CLSP) announced that Dr. Robert Kyle, Professor of Medicine and Laboratory Medicine at the Mayo Clinic in Rochester, Minnesota, has been appointed Chairman of Callisto’s Scientific Advisory Board. Dr. Kyle is an expert in the field of hematological cancers, with a special interest in the biology and management of multiple…

Callisto Pharmaceuticals Presents Preclinical Findings on Its Lead Drug Candidate for Multiple Myeloma

Callisto Pharmaceuticals, Inc. described its preclinical findings regarding the anticancer activities of its lead drug candidate, Atiprimod, in a poster at the Conference on Molecular Targets and Cancer Therapeutics, sponsored by the American Association for Cancer Research, the National Cancer Institute and the European Organization for Research and Treatment of Cancer which was held in…

Callisto Pharmaceuticals to Present Poster on Its Lead Drug Candidate for Multiple Myeloma at Conference on Molecular Targets and Cancer Therapeutics

NEW YORK, NY–(MARKET WIRE)–Nov 12, 2003 — Callisto Pharmaceuticals, Inc., (OTC BB: CLSP) today announced that a poster entitled Atiprimod is a Novel Anti-Angiogenic and Anti-Cancer Drug Candidate will be presented at the Conference on Molecular Targets and Cancer Therapeutics in Boston, November 17-20, 2003. The conference, sponsored by the American Association for Cancer Research,…

Callisto Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference

NEW YORK–(BUSINESS WIRE)–Oct. 21, 2003–Callisto Pharmaceuticals, Inc. (OTCBB: CLSP – News) announced today that it will participate in the Rodman & Renshaw Techvest Healthcare Conference, to be held October 21 – 23, 2003 at the Boston Marriott Long Wharf Hotel in Boston, MA. Gary S. Jacob, Ph.D., CEO of Callisto, is scheduled to speak at…